Justin J. McAnear - 01 Oct 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role: Chief Financial Officer
Signature: /s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol: TXG
Transactions as of: 01 Oct 2021
Net transactions value: -$1,384,821
Form type: 4
Filing time: 05 Oct 2021, 16:55:00 UTC
Previous filing: 03 Sep 2021
Next filing: 03 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXG	Class A Common Stock	Options Exercise	$50,400	+10,000	+26%	$5.04^*	49,100	01 Oct 2021	Direct	F1
transaction	TXG	Class A Common Stock	Sale	$90,003	-634	-1.3%	$141.96	48,466	01 Oct 2021	Direct	F1, F2
transaction	TXG	Class A Common Stock	Sale	$357,008	-2,500	-5.2%	$142.80	45,966	01 Oct 2021	Direct	F1, F3
transaction	TXG	Class A Common Stock	Sale	$814,725	-5,666	-12%	$143.79	40,300	01 Oct 2021	Direct	F1, F4
transaction	TXG	Class A Common Stock	Sale	$173,485	-1,200	-3%	$144.57	39,100	01 Oct 2021	Direct	F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXG	Stock Option (right to buy)	Options Exercise	$0	-10,000	-2.6%	$0.000000	380,159	01 Oct 2021	Class A Common Stock	10,000	$5.04	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2	This transaction was executed in multiple trades at prices ranging from $141.25 to $142.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3	This transaction was executed in multiple trades at prices ranging from $142.25 to $143.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4	This transaction was executed in multiple trades at prices ranging from $143.30 to $144.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5	This transaction was executed in multiple trades at prices ranging from $144.325 to $145.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6	This option, originally for 600,000 shares, of which 219,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.